Emergence of Exhausted B Cells in Asymptomatic HIV-1-Infected Patients Naïve for HAART is Related to Reduced Immune Surveillance

Table 2

Profiles of HAART-treated HIV-1-infected patients.

Donors	Sex	Age; (years)	HIV-1 risk group	HIV-1 viral load	CD4 T cell count; (cell/μL)	CDC before; therapy	Nadir	Therapy
1	M	44	Drug user	<50	481	A3	93	EFV+FTC+TDF
2	M	43	Drug user	<50	662	A2	201	NVP+3TC+TDF
3	F	34	Heterosex	<50	1124	A2	308	NVP+AZT+3TC
4	M	36	Homosex/bisex	<50	1031	C3	9	NVP+FTC+TDF
5	M	46	Drug user	<50	740	C3	43	AZT/r+FTC+TDF
6	M	60	Heterosex	<50	512	C3	39	AZT+3TC+ABC
7	M	48	Heterosex	<50	731	A2	208	NVP+3TC+ABC
8	M	53	Heterosex	<50	566	A3	94	EFV+FTC+TDF
9	M	44	Drug user	<50	527	C2	274	AZT/r+3TC+TDF
10	F	41	Heterosex	<50	636	A2	311	EFV+3TC+ABC
11	M	56	Homosex/bisex	<50	638	C3	84	AZT/r+3TC+ABC
12	M	40	Drug user	<50	823	A2	365	AZT+3TC+ABC
13	M	49	Heterosex	<50	754	A3	23	AZT+3TC+ABC
14	F	31	Drug user	<50	633	A2	280	FSP/r+3TC+ABC
15	F	49	Drug user	<50	846	B3	57	NVP+FTC+TDF
16	M	39	Homosex/bisex	<50	701	A2	332	AZT/r+FTC+TDF
17	F	43	Heterosex	<50	1067	A2	339	EFV+FTC+TDF
18	F	40	Drug user	<50	524	B3	166	NVP+3TC+ABC
19	M	44	Homosex/bisex	<50	701	A2	239	NVP+FTC+TDF
20	M	44	Heterosex	<50	564	C3	23	LPV/r+FTC+TDF

<50 HIV-1 RNA copies/mL: undetectable table.